Mitsui et al. demonstrate that, while CD4+ cells provide essential “help” to activate CD8+ cells, CD8+ are effectively able to kill tumor cells in mice that received injection of a murine colon carcinoma cell line after anti-GITR/anti-CTLA-4 combined treatment. This evidence concerns the gene TNFRSF18 and neoplasm.